Endocrine Abstracts

Background: Teprotumumab showed significant improvements vs placebo for the treatment of thyroid eye disease (TED) in clinical trials1,2 and is approved in the United States (US) but currently not in the EU. Differences exist in baseline patient demographics and characteristics between EU and US patients. Here we examine outcomes in these 2 cohorts.Methods: Data from the EU and US sites for patients in the teprotumumab group (n =121) from the in...

Objectives: Teprotumumab, an IGF1-receptor antagonist, has been shown in three clinical trials to markedly improve the clinical course of Thyroid Eye Disease (TED) or Graves’ Orbitopathy (GO) with significant improvements noted in inflammation, proptosis, and diplopia. Furthermore, compared to placebo moderate-to-large improvements were noted in the total, appearance (AP), and visual function (VF) as measured by EUGOGO GO quality of life (GO-QOL) scores after 24 weeks of ...